-  INCLUSION CRITERIA:

          -  Patients must have histologically confirmed solid tumors for which standard therapy
             known to prolong survival has failed in the metastatic setting or for which standard
             therapies do not exist.

          -  Tumor amenable to biopsy and willingness to undergo tumor biopsies before and after
             M6620 (VX-970) treatment during the expansion phase of the trial (biopsies optional
             during the escalation phase).

          -  Patients must have completed any chemotherapy, radiation therapy, surgery, or biologic
             therapy greater than or equal to 3 weeks (or greater than or equal to 5 half-lives,
             whichever is shorter) prior to entering the study. Patients must be greater than or
             equal to 2 weeks since any prior administration of a study drug in an exploratory
             IND/Phase 0 study and greater than or equal to 1 week since any palliative radiation
             therapy. Patients must have recovered to eligibility levels from prior toxicity or
             adverse events.

          -  Age greater than or equal to 18 years of age.

          -  ECOG performance status less than or equal to 2.

          -  Life expectancy > 3 months.

          -  Patients must have normal organ and marrow function as defined below:

               -  absolute neutrophil count greater than or equal to 1,500/mcL

               -  hemoglobin greater than or equal to 10 g/dL

               -  platelets greater than or equal to 100,000/mcL

               -  total bilirubin less than or equal to 1.5 X institutional upper limit of normal

               -  AST(SGOT)/ALT(SGPT) less than or equal to 1.5 X institutional upper limit of
                  normal (OR < 3X ULN in the setting of liver metastases)

               -  creatinine less than or equal to 1.5X institutional upper limit of normal

        OR

          -  creatinine clearance greater than or equal to 60 mL/min/1.73 m(2) for patients with
             creatinine levels above institutional normal

               -  The effects of M6620 (VX-970) and veliparib on the developing human fetus are
                  unknown. For this reason and because cisplatin is known to be teratogenic, women
                  of childbearing potential and men must agree to use adequate contraception
                  (hormonal or barrier method of birth control; abstinence) prior to study entry,
                  for the duration of study participation, and for 6 months after completing study
                  treatment. Should a woman become pregnant or suspect she is pregnant while she or
                  her partner is participating in this study, she should inform her treating
                  physician immediately. Men treated or enrolled on this protocol must also agree
                  to use adequate contraception prior to the study, for the duration of study
                  participation, and for 6 months after completion of administration of study
                  agents.

               -  HIV-positive subjects on combination antiretroviral therapy are ineligible
                  because of the potential for pharmacokinetic interactions with M6620 (VX-970). In
                  addition, these subjects are at increased risk of lethal infections when treated
                  with marrow-suppressive therapy.

               -  Patients must be able to swallow whole tablets or capsules. Nasogastric or G-tube
                  administration is not allowed. Any gastrointestinal disease which would impair
                  ability to swallow, retain, or absorb drug is not allowed.

               -  Ability to understand and the willingness to sign a written informed consent
                  document.

               -  During the expansion phase of the protocol, patients must have disease amenable
                  to biopsy and be willing to undergo pre- and post-treatment biopsies.

               -  Patients must have greater than or equal to 10.0 g/dL Hb and no blood transfusion
                  in the past 28 days to receive Veliparib.

        EXCLUSION CRITERIA:

          -  Patients who are receiving any other investigational agents.

          -  Patients with known active brain metastases or carcinomatous meningitis are excluded
             from this clinical trial. Patients whose brain metastatic disease status has remained
             stable for greater than or equal to 4 weeks following treatment of brain metastases
             are eligible to participate at the discretion of the principal investigator.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             untreated infection, or psychiatric illness/social situations that would limit
             compliance with study requirements.

          -  Patients required to be on any of the concomitant medications are excluded.

          -  Pregnant women and women who are breastfeeding are excluded from this study because
             the effects of the study drugs on the developing fetus are unknown.

          -  Patients who have had prior platinum-based therapy who have > Grade 1 neurotoxicity or
             ototoxicity at the time of enrollment will not be permitted on study.

          -  Patients with a seizure history will not be permitted on protocol due to association
             of veliparib with seizure activity in animal toxicology studies at higher doses.
             Patients on anticonvulsant medications will not be permitted on study due to the
             potential to lower plasma levels of anticonvulsants and risk for seizure activity.

          -  Patients with treatment-related AML (t-AML)/MDS, or with features suggestive of
             AML/MDS, or who have had prior allogeneic bone marrow transplant or double umbilical
             cord blood transplantation, should not receive Veliparib due to reports of MDS and
             leukemia secondary to oncology therapy on CTEP-sponsored studies utilizing Veliparib.

        INCLUSION of WOMEN and MINORITIES

        Both men and women of all races and ethnic groups are eligible for this trial.